Canaccord Reiterates Buy Rating on BridgeBio Pharma (BBIO)

October 7, 2026 6:45 AM EDT Send to a Friend
Canaccord analyst Whitney Ijem reiterated a Buy rating and $106.00 price target on BridgeBio Pharma (NASDAQ: BBIO).The analyst commented: "Yesterday ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login